CD Expression in Prostate Cancer

描述(申请人提供)：簇指定(CD)分子是在我们身体的各种细胞类型中差异表达的细胞表面抗原。前列腺的主要细胞类型可以通过它们的CD表达来识别。前列腺癌细胞的CD表型是在许多肿瘤检查中发现的CD10-/CD13-CD24/CD26+/CD38/CD57+/CDw75+/CD107b+，。除了CD_(10)和CD_(13)外，它类似于腔细胞的CD10+/CD13+/CD24+/CD26+/CD38+/CD57+/CDw75+/CD107b+模式，与基底细胞的CD10-/CD13-/CD24-/CD26-/CD38+/CD57-/CDw75-/CD107b-模式非常不同。因此，癌细胞与正常癌细胞不同之处在于CD10和CD13的表达缺失，CD24的表达增强，CD38的表达减弱或缺失。还发现了不同的癌症CD表型，如癌细胞CD10+。分析的原发肿瘤中约有25%含有CD10+癌细胞。与原发肿瘤不同的是，到目前为止，所有分析的淋巴转移都有CD10+癌细胞。顺便说一句，结节来源的细胞系LNCaP和异种移植的LuCaP 35都是CD10+。因此，前列腺癌可以通过它们的癌细胞类型的组成来表征，因此它们的行为受这些组成细胞类型的支配。某些癌细胞类型的存在将表明特定的病程(例如，转移到淋巴结)。因此，癌症CD表型可以用来将患者分成不同的预后组，并更准确地预测临床结果。虽然CD分子在不同类型的癌细胞中有不同的表达，但在几乎所有类型的癌细胞中都发现了几种CD分子，这些分子可以作为治疗播散性疾病的一种手段而被靶向杀死细胞。我们建议定义前列腺癌前病变、原发肿瘤和转移瘤中的前列腺细胞类型。这项研究对于更好地诊断前列腺癌和预后具有很大的潜力。采用体外三维细胞培养系统，研究CD10、CD13表达缺失对前列腺上皮细胞分化的影响。CD10和CD13都是多肽酶，可能参与生物活性信号肽的加工。它们的缺失可能导致癌细胞的异常分化和发展。

DESCRIPTION (provided by applicant): Cluster designation (CD) molecules are cell surface antigens differentially expressed among the various cell types of our body. The major cell types of the prostate can be identified by their CD expression. The CD phenotype for prostate cancer cells is CD10-/CD13-CD24/CD26+/CD38/CD57+/CDw75+/CD107b+, found for many tumors examined. It is like the CD10+/CD13+/CD24+/CD26+/CD38+/CD57+/CDw75+/CD107b+ pattern of luminal cells save for CD10 and CD13, and very unlike the CD10-/CD13-/CD24-/CD26-/CD38+/CD57-/CDw75-/CD107b- pattern of basal cells. Hence, cancer cells differ from their normal counterpart in the absent expression of CD10 and CD13, increased expression of CD24, and diminished or absent expression of CD38. Variant cancer CD phenotypes such as cancer cells scored CD10+ are also found. About 25% of the primary tumors analyzed contain CD10+ cancer cells. And unlike primary tumors, all lymph node metastases analyzed to date have CD10+ cancer cells. Incidentally, node-derived cell line LNCaP and xenograft LuCaP 35 are both CD10+. Prostate tumors can therefore be characterized by their composition of cancer cell types, and accordingly their behavior is governed by these constituent cell types. The presence of certain cancer cell types would indicate a particular disease course (metastasis to lymph nodes, for example). Thus, cancer CD phenotypes can be used to stratify patients into different prognostic groups and to predict clinical outcome more accurately. While there is differential expression of CD molecules among the cancer cell types several CD molecules are found in almost all types, and these molecules can be targeted for cell killing as a means to treat disseminated disease. We propose to define prostate cell type compositions in putative premalignant lesions, primary tumors and metastases. This study has great potential towards better prostate cancer diagnosis and prognosis. An in vitro three-dimensional cell culture system will be used to study the effect of absent CD10 or CD13 expression in prostate epithelial cell differentiation. CD10 and CD13 are both peptidases and are likely involved in the processing of bioactive signaling peptides. Their absence might lead to the aberrant cellular differentiation and development of cancer.